Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
NRG Oncology
National Cancer Institute (NCI)
Mayo Clinic
SWOG Cancer Research Network
Mayo Clinic
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
Stanford University
Wake Forest University Health Sciences
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
City of Hope Medical Center
National Cancer Institute (NCI)
Thomas Jefferson University
Roswell Park Cancer Institute
University of Michigan Rogel Cancer Center
Mayo Clinic
Mayo Clinic
Mayo Clinic
Emory University